UNSPSC 51314360: Diphenhydramine/phenylephrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.

UNSPSC 51314360 Diphenhydramine/phenylephrine is a Commodity code that describes individual pharmaceutical products, but the recent state and local opportunities posted under this code show a broader pattern of government procurement for pharmaceuticals and pharmacy benefit programs rather than the narrow product category the code nominally covers. Seminole County, Florida is procuring naloxone and drug deactivation systems through an IFB; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is soliciting generic multi-source pharmaceuticals and OTC products through an RFP; and the Texas Health and Human Services Commission issued an RFI to explore direct-to-manufacturer prescription programs. State and local buyers soliciting under this code include county health departments, multistate cooperative purchasing consortia, and state health agencies. The scope spans both specific pharmaceutical products (naloxone, generic pharmaceuticals, OTC drugs) and broader pharmacy benefit program administration and supply-chain strategies, suggesting the code captures diverse pharmaceutical procurement activity across health and human services.

Recent opportunities show activity centered in the South and Upper Midwest. Seminole County's naloxone procurement (IFB 60459723LAS, due July 26, 2023) calls for 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly delivery to Sanford, Florida; the contract includes a two-year initial term with one-year renewal option and is potentially FEMA-funded. Minnesota's MMCAP RFP (S1070000015802, due March 26, 2026) establishes multiple contracts for generic pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with awards effective July 1, 2026, and pricing weighted 75 percent on competitiveness; vendors must maintain relationships with at least two of three authorized wholesalers and comply with cGMP and DSCSA requirements. Texas HHS's RFI (HHS0017013, response deadline April 3, 2026) represents early-stage market research into direct-to-manufacturer prescription fulfillment without PBM intermediaries, suggesting Texas is exploring alternative pharmacy benefit strategies before issuing formal procurement.